Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Portal Hypertension Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Portal Hypertension Overview | 7 | 1 |
| Portal Hypertension Therapeutics under Development by Companies | 8 | 1 |
| Portal Hypertension Pipeline Products Glance | 9 | 2 |
| Clinical Stage Products | 9 | 1 |
| Early Stage Products | 10 | 1 |
| Portal Hypertension Products under Development by Companies | 11 | 1 |
| Portal Hypertension Companies Involved in Therapeutics Development | 12 | 6 |
| Conatus Pharmaceuticals Inc. | 12 | 1 |
| Cumberland Pharmaceuticals, Inc. | 13 | 1 |
| Galectin Therapeutics, Inc. | 14 | 1 |
| Genextra S.p.a. | 15 | 1 |
| LinXis B.V. | 16 | 1 |
| Mezzion Pharma Co. Ltd. | 17 | 1 |
| Portal Hypertension Therapeutics Assessment | 18 | 9 |
| Assessment by Monotherapy Products | 18 | 1 |
| Assessment by Target | 19 | 2 |
| Assessment by Mechanism of Action | 21 | 2 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| Drug Profiles | 27 | 33 |
| emricasan Drug Profile | 27 | 6 |
| GRMD-02 Drug Profile | 33 | 11 |
| ifetroban sodium Drug Profile | 44 | 2 |
| LIN-003 Drug Profile | 46 | 1 |
| obeticholic acid Drug Profile | 47 | 10 |
| udenafil Drug Profile | 57 | 3 |
| Portal Hypertension Dormant Projects | 60 | 1 |
| Portal Hypertension Discontinued Products | 61 | 1 |
| Portal Hypertension Product Development Milestones | 62 | 6 |
| Featured News &Press Releases | 62 | 1 |
| Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting | 62 | 1 |
| ep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis | 62 | 2 |
| Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting | 64 | 1 |
| Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting | 65 | 1 |
| Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension | 65 | 1 |
| Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting | 66 | 2 |
| Appendix | 68 | 2 |
| Methodology | 68 | 1 |
| Coverage | 68 | 1 |
| Secondary Research | 68 | 1 |
| Primary Research | 68 | 1 |
| Expert Panel Validation | 68 | 1 |
| Contact Us | 68 | 1 |
| Disclaimer | 69 | 1 |